Biosimilars With Foreign Comparator Data Could Open U.S. FDA To Criticism
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA’s biosimilars draft guidance documents contained a few surprising provisions, including a willingness to accept comparative data referencing a biologic product that is not approved in the U.S., a Covington and Burling attorney says.